Hildegund CJ Ertl, MD

Professor
The Wistar Institute
Philadelphia, Pennsylvania, United States

Hildegund Ertl, M.D.

Dr. Ertl is a Professor at The Wistar Institute and a member of the institute’s Vaccine Center. Her current research interests fall into six broad categories: HIV vaccines, human papilloma virus vaccines, rabies vaccine models ,therapeutic vaccine to chronic HBV infection and improving active immunotherapy of cancer through metabolic manipulation of tumor infiltrating lymphocytes The Ertl laboratory has pioneered numerous patented technologies to create new vaccines. Much of the laboratory’s efforts on developing a new preventative vaccine for rabies—a disease that retains a disastrous presence in places across the globe—have yielded useful technologies that the Ertl laboratory is applying to combating other viruses. This includes utilizing a modified chimpanzee virus as a vaccine carrier to induce an immune response against HIV, and a new therapeutic vaccine against human papillomavirus (HPV), a leading cause of cervical cancer. Dr. Ertl came to The Wistar Institute as an associate professor in 1987. A native of Euskirchen, Germany, she received her medical degree from University of Göttingen. While in medical school, she began her scientific training as a student in the Max Planck Institute of Experimental Medicine. After research fellowships at the Australian National University and the University of Minnesota, Dr. Ertl joined the faculty of Harvard University before transitioning to Wistar. She became a full professor at Wistar in 1996 and holds adjunct professorships at the University of Pennsylvania School of Medicine and The Children’s Hospital of Philadelphia.

I do not have any relevant financial / non-financial relationships with any proprietary interests.

Presentation(s):

• 2320 - Novel checkpoint modifier lowers T cell activation threshold and enhances and broadens vaccine-induced responses to chronic viral infections

  Saturday, October 22, 2022
  2:15 PM – 2:30 PM US ET